134 related articles for article (PubMed ID: 28845536)
1. Prevalence and determinants of end-of-life chemotherapy use in patients with metastatic breast cancer.
Mathew A; Achkar T; Abberbock S; Sandhu GS; Jacob ME; Villgran VD; Rosenzweig MQ; Puhalla S; Brufsky AM
Breast J; 2017 Nov; 23(6):718-722. PubMed ID: 28845536
[TBL] [Abstract][Full Text] [Related]
2. The aggressiveness of cancer care in the last three months of life: a retrospective single centre analysis.
Braga S; Miranda A; Fonseca R; Passos-Coelho JL; Fernandes A; Costa JD; Moreira A
Psychooncology; 2007 Sep; 16(9):863-8. PubMed ID: 17245696
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.
von Minckwitz G; Puglisi F; Cortes J; Vrdoljak E; Marschner N; Zielinski C; Villanueva C; Romieu G; Lang I; Ciruelos E; De Laurentiis M; Veyret C; de Ducla S; Freudensprung U; Srock S; Gligorov J
Lancet Oncol; 2014 Oct; 15(11):1269-78. PubMed ID: 25273342
[TBL] [Abstract][Full Text] [Related]
4. Oral etoposide in heavily pre-treated metastatic breast cancer: A retrospective series.
Giannone G; Milani A; Ghisoni E; Genta S; Mittica G; Montemurro F; Valabrega G
Breast; 2018 Apr; 38():160-164. PubMed ID: 29413403
[TBL] [Abstract][Full Text] [Related]
5. Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.
Foukakis T; von Minckwitz G; Bengtsson NO; Brandberg Y; Wallberg B; Fornander T; Mlineritsch B; Schmatloch S; Singer CF; Steger G; Egle D; Karlsson E; Carlsson L; Loibl S; Untch M; Hellström M; Johansson H; Anderson H; Malmström P; Gnant M; Greil R; Möbus V; Bergh J;
JAMA; 2016 Nov; 316(18):1888-1896. PubMed ID: 27825007
[TBL] [Abstract][Full Text] [Related]
6. Determinants of Last-line Treatment in Metastatic Breast Cancer.
Cinausero M; Gerratana L; De Carlo E; Iacono D; Bonotto M; Fanotto V; Buoro V; Basile D; Vitale MG; Rihawi K; Fasola G; Puglisi F
Clin Breast Cancer; 2018 Jun; 18(3):205-213. PubMed ID: 28781022
[TBL] [Abstract][Full Text] [Related]
7. Association between survival time with metastatic breast cancer and aggressive end-of-life care.
Accordino MK; Wright JD; Vasan S; Neugut AI; Gross T; Hillyer GC; Hershman DL
Breast Cancer Res Treat; 2017 Nov; 166(2):549-558. PubMed ID: 28752188
[TBL] [Abstract][Full Text] [Related]
8. Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting.
Generali D; Montemurro F; Bordonaro R; Mafodda A; Romito S; Michelotti A; Piovano P; Ionta MT; Bighin C; Sartori D; Frassoldati A; Cazzaniga ME; Riccardi F; Testore F; Vici P; Barone CA; Schirone A; Piacentini F; Nolè F; Molino A; Latini L; Simoncini EL; Roila F; Cognetti F; Nuzzo F; Foglietta J; Minisini AM; Goffredo F; Portera G; Ascione G; Mariani G
Oncologist; 2017 Jun; 22(6):648-654. PubMed ID: 28432226
[TBL] [Abstract][Full Text] [Related]
9. Psychological factors at early stage of treatment as predictors of receiving chemotherapy at the end of life.
Fujisawa D; Temel JS; Traeger L; Greer JA; Lennes IT; Mimura M; Pirl WF
Psychooncology; 2015 Dec; 24(12):1731-7. PubMed ID: 25959002
[TBL] [Abstract][Full Text] [Related]
10. Factors responsible for long-term survival in metastatic breast cancer.
Kontani K; Hashimoto S; Murazawa C; Norimura S; Tanaka H; Ohtani M; Fujiwara-Honjo N; Date M; Teramoto K; Houchi H; Yokomise H
World J Surg Oncol; 2014 Nov; 12():344. PubMed ID: 25395387
[TBL] [Abstract][Full Text] [Related]
11. Hospice utilization and end-of-life care in metastatic breast cancer patients at a comprehensive cancer center.
O'Connor TL; Ngamphaiboon N; Groman A; Luczkiewicz DL; Kuszczak SM; Grant PC; Kerr CW
J Palliat Med; 2015 Jan; 18(1):50-5. PubMed ID: 25353618
[TBL] [Abstract][Full Text] [Related]
12. The economic burden of end-of-life care in metastatic breast cancer.
Bramley T; Antao V; Lunacsek O; Hennenfent K; Masaquel A
J Med Econ; 2016 Nov; 19(11):1075-1080. PubMed ID: 27248201
[TBL] [Abstract][Full Text] [Related]
13. Aggressiveness of cancer-care near the end-of-life in Korea.
Keam B; Oh DY; Lee SH; Kim DW; Kim MR; Im SA; Kim TY; Bang YJ; Heo DS
Jpn J Clin Oncol; 2008 May; 38(5):381-6. PubMed ID: 18411260
[TBL] [Abstract][Full Text] [Related]
14. Discrepancies in the use of chemotherapy and artificial nutrition near the end of life for hospitalised patients with metastatic gastric or oesophageal cancer. A countrywide, register-based study.
Kempf E; Tournigand C; Rochigneux P; Aubry R; Morin L
Eur J Cancer; 2017 Jul; 79():31-40. PubMed ID: 28458120
[TBL] [Abstract][Full Text] [Related]
15. Counterpoint: the argument for combination chemotherapy in the treatment of metastatic breast cancer.
Cianfrocca M; Gradishar WJ
J Natl Compr Canc Netw; 2007 Sep; 5(8):673-5. PubMed ID: 17927925
[TBL] [Abstract][Full Text] [Related]
16. Polychemotherapy for early breast cancer: results from the international adjuvant breast cancer chemotherapy randomized trial.
Adjuvant Breast Cancer Trials Collaborative Group
J Natl Cancer Inst; 2007 Apr; 99(7):506-15. PubMed ID: 17405995
[TBL] [Abstract][Full Text] [Related]
17. Oral metronomic cyclophosphamide with and without methotrexate as palliative treatment for patients with metastatic breast carcinoma.
Gebbia V; Boussen H; Valerio MR
Anticancer Res; 2012 Feb; 32(2):529-36. PubMed ID: 22287742
[TBL] [Abstract][Full Text] [Related]
18. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer.
Farhat F; Kattan JG; Ghosn M
Cancer Chemother Pharmacol; 2016 May; 77(5):1069-77. PubMed ID: 27059339
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome.
Ibrahim NK; Frye DK; Buzdar AU; Walters RS; Hortobagyi GN
Arch Intern Med; 1996 Apr; 156(8):882-8. PubMed ID: 8774207
[TBL] [Abstract][Full Text] [Related]
20. A Randomized, Open-Label, Multicenter, Phase III Study of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy.
Leyland-Jones B; Bondarenko I; Nemsadze G; Smirnov V; Litvin I; Kokhreidze I; Abshilava L; Janjalia M; Li R; Lakshmaiah KC; Samkharadze B; Tarasova O; Mohapatra RK; Sparyk Y; Polenkov S; Vladimirov V; Xiu L; Zhu E; Kimelblatt B; Deprince K; Safonov I; Bowers P; Vercammen E
J Clin Oncol; 2016 Apr; 34(11):1197-207. PubMed ID: 26858335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
